Xintela publishes safety and efficacy results from knee osteoarthritis clinical study with XSTEM in scientific journal

The positive results from Xintela’s (XINT) clinical study (Phase I/IIa) on XSTEM for knee osteoarthritis have now been published in the peer-reviewed scientific journal Cartilage. The results show in addition to safety that the XSTEM treatment reduced knee pain, improved joint function and improved cartilage and bone tissue, supporting a disease-modifying effect of XSTEM. The […]

Xintela raises a convertible loan of SEK 30 million

Xintela has entered into an agreement to raise a convertible loan of SEK 30 million from the Company’s principal shareholder, Flerie Invest, to accelerate the development of XSTEM® for the treatment of osteoarthritis, to repay the previous loan from Fenja Capital II and to meet the Company’s general working capital requirements. Xintela AB (publ) (“Xintela” […]

Xintela reports safety results from the XSTEM clinical study in difficult-to-heal venous leg ulcers

Xintela announces that the XSTEM® treatment in the clinical Phase I/IIa study on patients with difficult-to-heal venous leg ulcers was considered safe and well tolerated and thus achieved the primary objective of the study. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Xintela’s completed Phase I/IIa […]

Xintela AB changes Certified Adviser to Västra Hamnen Corporate Finance AB

Xintela AB announces today that the company is changing its Certified Adviser to Västra Hamnen Corporate Finance AB. Xintela AB has entered into an agreement with Västra Hamnen Corporate Finance AB regarding the role as Certified Adviser. Västra Hamnen Corporate Finance AB will assume the role of Certified Adviser on June 1, 2026. Until then, […]

Xintela granted US patent for XSTEM treatment of difficult-to-heal wounds and skin defects

Xintela (XINT) announces today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of the company’s stem cell product XSTEM® for the treatment and regeneration of skin defects, including difficult-to-heal (chronic) wounds. The patent, US 12,599,633, issues today and protects XSTEM in the United States until 7 June […]

Xintela publication on EQSTEM treatment of horses in a preclinical osteoarthritis study awarded best basic science paper

The results from Xintela’s preclinical EQSTEM® study in horses with post-traumatic osteoarthritis (OA) has previously been published in the scientific journal Cartilage. The results show less pain and less cartilage damage after treatment with the stem cell product EQSTEM, indicating a disease modifying effect of EQSTEM. The publication has now been awarded best basic science […]

Xintela completes clinical study with XSTEM in difficult-to-heal leg ulcers

Xintela (XINT) announces that the company’s clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg ulcers has been completed with the last follow-up visit for the last patient. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Xintela’s Phase I/IIa clinical study in patients […]

Last patient dosed in Xintela’s clinical study on difficult-to-heal leg ulcers

Xintela (XINT) announces that the last patient has been dosed in the company’s clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg ulcers. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Xintela’s ongoing Phase I/IIa clinical study in patients with difficult-to-heal venous leg […]

Xintela announces subsidiary Targinta collaboration with MSK Therapeutics Accelerator

Xintela (XINT) announces that Xintela’s oncology subsidiary, Targinta AB, has today initiated a collaboration with Memorial Sloan Kettering Cancer Center’s (MSK’s) Therapeutics Accelerator in New York, USA, for development of its integrin α10β1 antibody therapeutic in patients with aggressive sarcoma. Under the collaboration, Targinta will produce antibodies targeting integrin α10β1 and complete preclinical development work […]